Business Context and Reporting Period
This Form 8-K is a current report filed by Tivic Health Systems, Inc. (not Valion Bio, Inc.) on March 6, 2025. The registrant is a Delaware corporation with principal executive offices in Fremont, California, and its common stock trades on The Nasdaq Stock Market under the symbol TIVC. The company identifies itself as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific corporate event rather than financial performance data.
Material Changes
The material event reported is the presentation of new clinical data at the Sixth Biometric Medicine Summit. The data, presented in a poster, indicates that personalizing the company's non-invasive vagus nerve stimulation method optimizes the stimulation's impact on autonomic nervous system activity.
Guidance, Outlook, and Risks
- Management Commentary: The company issued a press release (Exhibit 99.1) detailing the new data regarding its vagus nerve stimulation technology.
- Forward-Looking Statements: The report contains forward-looking statements involving substantial risks and uncertainties. Terms such as "anticipates," "expects," and "believes" identify these statements.
- Risks: Actual results may differ materially from those expressed due to known and unknown risks, including those set forth in other SEC filings. These factors could adversely affect the company's business, financial performance, and operating achievements.
Investor Verification Checklist
- Verify the full text of the press release furnished as Exhibit 99.1 for specific details on the clinical data.
- Confirm the company name is Tivic Health Systems, Inc. (TIVC), as the input metadata referenced "Valion Bio, Inc."
- Review the company's most recent 10-K or 10-Q filings for actual financial metrics, as this 8-K contains none.
- Assess the implications of the "emerging growth company" status on financial reporting standards.